You are now leaving XifaxanHE.com

Thank you for visiting XifaxanHE.com. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).

OKCancel

ABOUT HE

How is overt hepatic encephalopathy (HE) managed?

It’s important to understand that there are certain risks involved with having overt HE. Ongoing management can help reduce those risks.

Once an episode of overt HE happens, ongoing management is recommended to help reduce the risk of another episode. This is called maintenance therapy.

The focus of maintenance therapy is to reduce the toxins in the body that can lead to additional overt HE episodes. The most commonly prescribed treatments are:

The safety and efficacy of XIFAXAN in HE patients has not been studied for longer than 6 months in clinical trials.
If patients recover a significant amount of liver function, they may be able to discontinue HE therapy.

Round button with nurse icon that reads Enroll in H.E.L.P. for support Round button with nurse icon that reads Enroll in H.E.L.P. for support

*Eligibility criteria, terms and conditions apply.

Lactulose

Lactulose is an artificial sugar. It comes as a very sweet liquid that is taken by mouth. It can also be given as an enema for people who cannot swallow.

Lactulose works by causing more bowel movements. This helps to flush out the toxins that are produced in the gut.

The amount of lactulose that a person with overt HE must take each day has to be adjusted so that he or she has 2-3 bowel movements each day.

Lactulose is a very sweet liquid that is taken by mouth

XIFAXAN 

XIFAXAN is an antibiotic that helps reduce the amount of toxins in the gut. It comes as a 550 mg tablet that is taken by mouth 2 times a day to reduce the risk of an overt HE recurrence in adults.

Xifaxan is a tablet that is taken by mouth

LEARN MORE ABOUT XIFAXAN

HE experts recommend adding XIFAXAN to lactulose for HE management to help reduce the risk of an overt HE recurrence.

The safety and efficacy of XIFAXAN in HE patients has not been studied for longer than 6 months in clinical trials.
If patients recover a significant amount of liver function, they may be able to discontinue HE therapy.

WHY IS MANAGEMENT FOR OVERT HE IMPORTANT?

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets in HE

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • XIFAXAN has not been studied in people with MELD scores over 25 and only 8.6% of people in the controlled study had MELD scores over 19. There is an increased chance that XIFAXAN will spread through your body if you have more severe hepatic dysfunction. Therefore, if you have severe hepatic impairment, which is a Child-Pugh score of C, you should talk to your healthcare provider before taking XIFAXAN.
  • Tell your doctor if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because it is unknown if XIFAXAN can harm an unborn baby or nursing infant.
  • In the clinical study, the most common side effects in HE associated with XIFAXAN 550 mg tablets—occurring in at least 10% of people receiving XIFAXAN—were peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: valeantmc@dlss.com

Please click here for full Prescribing Information for XIFAXAN.

See MoreImportant Safety Information
See LessImportant Safety Information

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets in HE

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • XIFAXAN has not been studied in people with MELD scores over 25 and only 8.6% of people in the controlled study had MELD scores over 19. There is an increased chance that XIFAXAN will spread through your body if you have more severe hepatic dysfunction. Therefore, if you have severe hepatic impairment, which is a Child-Pugh score of C, you should talk to your healthcare provider before taking XIFAXAN.
  • Tell your doctor if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because it is unknown if XIFAXAN can harm an unborn baby or nursing infant
  • In the clinical study, the most common side effects in HE associated with XIFAXAN 550 mg tablets—occurring in at least 10% of people receiving XIFAXAN—were peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: valeantmc@dlss.com

Please click here for full Prescribing Information for XIFAXAN.